NCT01091103View on ClinicalTrials.gov

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 18, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

August 31, 2013

Conditions
Metastatic Progressive Castration-resistant Prostate Cancer
Interventions
DRUG

Enzalutamide

Trial Locations (1)

77303

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT01091103 - Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | Biotech Hunter | Biotech Hunter